-+ 0.00%
-+ 0.00%
-+ 0.00%

ROYALTY PHARMA ACQUIRES ROYALTY INTEREST IN NUVALENT’S NELADALKIB AND ZIDESAMTINIB FOR UP TO $315 MILLION

Reuters·12/16/2025 12:15:00

Please log in to view news